Review Article

Chorioamnionitis and Lung Injury in Preterm Newborns

Gustavo Rocha

Division of Neonatology, Department of Pediatrics, São João Hospital, 4202-451 Porto, Portugal

Correspondence should be addressed to Gustavo Rocha; gusrocha@oninet.pt

Received 24 July 2012; Accepted 13 December 2012

Academic Editor: Manuel Sánchez Luna

Copyright © 2013 Gustavo Rocha. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

There is a strong evidence that histologic chorioamnionitis is associated with a reduction of incidence and severity of respiratory distress syndrome (RDS). Short-term maturational effects on the lungs of extremely premature infants seem to be, however, accompanied by a greater susceptibility of the lung, eventually contributing to an increased risk of bronchopulmonary dysplasia (BPD). Genetic susceptibility to BPD is an evolving area of research and several studies have directly related the risk of BPD to genomic variants. There is a substantial heterogeneity across the studies in the magnitude of the association between chorioamnionitis and BPD, and whether or not the association is statistically significant. Considerable variation is largely dependent on differences of inclusion and exclusion criteria, as well as on clinical and histopathological definitions. The presence of significant publication bias may exaggerate the magnitude of the association. Controlling for publication bias may conduct to adjusted results that are no longer significant. Recent studies generally seem to confirm the effect of chorioamnionitis on RDS incidence, while no effect on BPD is seen. Recent data suggest susceptibility for subsequent asthma to be increased on long-term followup. Additional research on this field is needed.

1. Introduction

Watterberg and colleagues [1] were the first to report, in 1996, a decrease in the incidence of respiratory distress syndrome (RDS), while the incidence of chronic lung injury, marked by the presence of bronchopulmonary dysplasia (BPD), was increased in preterm newborns with histological chorioamnionitis. This paradoxical effect of prenatal inflammation on pulmonary outcome has been referred to as the “Watterberg effect.” Since then, the effects of antenatal inflammation on both short- and long-term pulmonary outcome have received increasing attention, and many studies have been reported over the last years.

Chorioamnionitis is the leading cause of very preterm delivery and its incidence increases with decreasing gestational age [2–5].

BPD is one of the most frequent sequelae in very preterm infants and results in increased healthcare costs, prolonged hospital stays with frequent readmissions, and deleterious effects on subsequent growth and neurodevelopment [6, 7]. BPD is mostly multifactorial and a complex view of its pathogenesis (“multiple hits” hypothesis) has emerged, which includes antenatal exposure to a proinflammatory environment together with various postnatal inflammation-triggering events such as mechanical ventilation, sepsis, and patent ductus arteriosus [6, 8–10]. The “new” BPD results from an arrest of alveolar development with minimal fibrosis, associated with preterm birth, and is different from the “typical” BPD that follows severe RDS [6].

While the literature is consistent with the association between histological chorioamnionitis and a decreased incidence of RDS in the preterm newborn, many studies have found no association between chorioamnionitis and BPD [11, 12].

The purpose of this paper is to provide the actual evidence on neonatal pulmonary outcome after exposure to intrauterine inflammation.

2. Experimental Models of Inflammatory Neonatal Lung Injury

Animal models of intrauterine inflammation/infection provided evidence for altered lung development, with accelerated functional maturation and arrested alveolarization and vascular development. These models also demonstrated
the central role of the developing immune system in the pathogenesis of lung injury.

In the sheep model [9, 13], sterile chorioamnionitis caused by a single injection of Escherichia coli lipopolysaccharide stimulated pulmonary inflammation with increased expression of proinflammatory mediators as cytokines, chemokines, monocyte chemoattractant protein, recruitment of polymorphonuclear cells and monocytes, maturation of monocytes to alveolar macrophages, increased secretion of surfactant proteins and phospholipids, and arrested alveolar and microvascular development. This experimental model demonstrated both, a maturational response with increased pulmonary compliance, as well as aberrant structural changes on the developing lung. Injection of Escherichia coli lipopolysaccharide into the amniotic fluid of E15 BALB/c mice [14] increased the luminal volume density of fetal mouse lungs at embryonic day (E) 17 and E18. Lipopolysaccharide also increased luminal volume and decreased distal lung branching in fetal mouse lung explants. This effect required NF-kappaB activation and functional Toll-Like receptor 4. Airway branching may require fibronectin-dependent epithelial-mesenchymal interactions, representing a potential target for innate immune signaling. Antifibronectin antibodies and lipopolysaccharide both blocked distal lung branching. By immunofluorescence, fibronectin localized to the clefts between newly formed airways but was restricted to peripheral mesenchymal cells in lipopolysaccharide-exposed explants. These data suggest that lipopolysaccharide may alter the expression pattern of mesenchymal fibronectin, potentially disrupting epithelial-mesenchymal interactions and inhibiting distal airway branching and alveolarization. This mechanism may link innate immune signaling with defects in structural development of the fetal lung.

Two studies [15, 16] on a transgenic mouse model revealed that human cytokine-1 beta expression in the saccular stage was sufficient to cause a BPD-like illness in infant mice, whereas the lung was more resistant to cytokine-1 beta induced injury at later developmental stages. This is consistent with the clinical observation that extreme prematures (23–27 weeks, early saccular stage) are at the highest risk for inflammation-mediated BPD, whereas infants over 32 weeks (late saccular-alveolar stage) are at much lower risk.

3. Experimental Models of Ureaplasma Intrauterine Infection

The genital mycoplasmas Ureaplasma urealyticum and Ureaplasma parvum are the most common organisms isolated in the amniotic fluid in women with preterm labor and the rate of vertical transmission increases with the duration of membrane rupture [17, 18]. Although the ascending infection at or near the time of delivery has been pointed as the most common route of infection, Ureaplasmas have been detected in 13% of amniotic fluid samples at the time of genetic amniocentesis, at 16–20 weeks gestation, in asymptomatic women, indicating possible prolonged subclinical infection [17]. There is now considerable clinical and experimental evidence that these organisms contribute to chorioamnionitis, fetal inflammatory response, preterm birth, and neonatal morbidities including BPD, intraventricular hemorrhage, and necrotizing enterocolitis [13, 17, 19–28]. Pathologic changes in Ureaplasma-infected lungs of preterm infants are characterized by moderate-severe fibrosis, disordered elastin accumulation, myofibroblast accumulation, and chronic inflammation [29, 30].

Intrauterine Ureaplasma infection models in nonhuman primates [22, 26, 31], sheep [13], and mice [32] closely mimic the human exposure during early stages of lung development. In all intrauterine models, Ureaplasma organisms established a persistent infection in the intrauterine compartment, indicating limited capacity to clear these organisms. The findings of these studies suggest that Ureaplasma infection causes an imbalance of proinflammatory, profibrotic, and anti-inflammatory, antibacterial factors in the fetal lung that may be augmented by postnatal exposure to hyperoxia and mechanical ventilation.

Humans are the specific host for Ureaplasma parvum and Ureaplasma urealyticum, so the organisms may elicit a less robust response in less related species. Alternatively, as shown in the mouse model, acute inflammation occurring during the saccular stage but not other stages of lung development results in arrested alveolarization, and airway remodelling typical of human BPD.

4. Genetic Susceptibility

Several studies have directly related the risk of BPD to genomic variants [33]. Polymorphisms of cytokines (IFNy +1267 C), adhesion molecules (L-selectin-Prot213Ser), elements of rennin-angiotensin system (ACE-I/D), antioxidant enzymes (GST-P1 Val105Ile), and surfactant proteins (SPA1, SPB intron4) have been identified as risk factors for BPD. Other studies investigated the role of genotype in BPD risk factors. Premature birth has been linked to polymorphisms with an impact on immune status (such as IL-6 G–174 C, MBL2 54G/A, VEGF G+405 C, and HSP72A +1267 G genes) and matrix metalloproteases. Fetal inflammatory response syndrome, a major determinant of BPD, is also affected by genotype (including LTA +250 G) [33].

In our pilot study [34], HLA-A*68, -B*51, and -Cw7 14 were the human major histocompatibility complex alleles associated with oxygen requirement at 36 weeks postmenstrual age in preterm neonates less than 32 weeks gestational age. The idea that an autoimmune process might be involved in BPD pathogenesis is novel and needs further investigation.

Twin concordance studies have suggested that the contribution of genetic risk to BPD is high, accounting for 35%–65% risk for the outcome [35, 36].

The challenges of enrolling adequate sample size in the preterm population, racial/ethnic heterogeneity in populations, variations in clinical practices, and the multifactorial pathogenesis of BPD make genetic studies difficult to be performed and may be responsible for the fact that some associations have not been replicated in subsequent studies.
5. Chorioamnionitis and Neonatal Respiratory Outcome in Preterm Infants

The primary process in the aetiology of intrauterine inflammation is believed to be ascending bacterial invasion from the cervicovaginal tract, although several other routes have been postulated [2, 37]. Extraneous infections such as periodontitis, pneumonia, and urinary tract infections are risk factors for preterm birth [38, 39]. In the rodent model, maternal systemic inflammation resulted in prolonged pulmonary inflammation postnatally and a BPD phenotype [39].

Clinical chorioamnionitis does not correlate well with histological chorioamnionitis or culture positive amniotic fluid [40]. Histopathological examination of the placenta is the gold standard for evaluating antenatal inflammatory processes that might influence fetal development. Histological chorioamnionitis develops through a well-characterized stereotyped progression of maternal and fetal cellular stages that vary from patient to patient and are amenable to quantification. Increases in the intensity of these responses and their gradual transformation into a chronic phase are important variables that can adversely affect fetal physiology. Under recognised placental inflammatory lesions affecting the decidua, placental villi and fetal vessels are also potentially informative factors that should be taken into account in the studies of adverse pregnancy outcomes [37].

Most deliveries before 30 weeks gestation (saccular stage of lung development) are associated with histological chorioamnionitis, which is often clinically silent [2]. The more preterm the delivery, the more often the histological chorioamnionitis is detected [3]. Most infants delivered before 30 weeks gestation also have amniotic fluid that is culture positive for low pathogenic organisms such as Ureaplasma and Mycoplasma [2].

Lung inflammation is defined as increased inflammatory cells in the airspaces and lung tissue that are producing proinflammatory mediators such as hydrogen peroxide, interleukin 1, and interleukin 8 [40]. Lung inflammation starting before delivery with chorioamnionitis may continue as a result of routine care practices (ventilation, oxygen exposure), and adverse clinical events, such as nosocomial infection. The proinflammation is counterbalanced by anti-inflammatory effects of antenatal steroids, because about 80% or preterm infants are exposed to betamethasone or dexamethasone [40]. Postnatal steroids also acutely decrease indicators of inflammation. Both antenatal and postnatal steroids inhibit alveolar septation. Both proinflammatory and anti-inflammatory mediators disrupt alveolarization and to date no treatments are available to promote alveolarization [40].

Histological chorioamnionitis is defined by a maternal inflammatory response with neutrophilic infiltration of the membranes and/or chorionic plate. Fetal inflammation has been defined as either choriocarcinoma [41], umbilical vasculitis [4], funisitis [42–45], “fetal response” [46], or subdivided into polymorphonuclear leukocyte infiltration of the chorionic plate or the umbilical cord [47]. Some studies showed that the RDS incidence was further decreased in infants with fetal involvement when compared to those with only maternal signs of inflammation [4, 41, 45, 47], an effect that appears to be additive to that of chorioamnionitis alone [4]. None of the studies found fetal inflammation to increase the risk of developing BPD, when compared to only maternal inflammation.

The studies where the association between chorioamnionitis and RDS has been assessed presented either similar [34, 43, 45, 48–52] or decreased [1, 4, 5, 47, 53, 54] RDS incidences. Today, it is generally accepted that there is enough evidence to consider that histological chorioamnionitis is associated with a reduction of incidence and severity of RDS [11, 12, 55].

Data on the need for respiratory support after chorioamnionitis differ greatly between studies. Often parallel to RDS incidence, chorioamnionitis has been reported to increase [49, 52] and decrease [53], as well not to affect the need for surfactant administration [42]. Moreover, while some report no effect on the need for mechanical ventilation [52, 53], time spent on the ventilator [48], and time on additional oxygen supplementation [48], others report increased need for ventilatory support or oxygen [51, 52].

The association between chorioamnionitis and BPD has been assessed in several studies, yielding inconsistent results. In order to clarify this issue, Hartling and colleagues [12] conducted a systematic review including an extensive and comprehensive search, duplicate screening, inclusion and data extraction to reduce bias, and metaregression to control for potential confounders. The authors identified 3,587 potentially relevant studies, of which 59 (15,295 patients) met the inclusion criteria. Studies were included if they had a comparison group, if they examined preterm or low birth weight infants, and reported primary data that could be used to measure the association between exposure to chorioamnionitis and the development of BPD. Studies classified chorioamnionitis as either clinical, histological, or microbiological. BPD was classified in the different studies as either (1) “Northway”: X-ray abnormalities persisting beyond one month of age in patients who continued to require oxygen or respiratory support; (2) “Bancalari”: need for oxygen on 28 of the first 28 days of life together with a compatible chest radiograph (or need for oxygen at 28 days of age, i.e., the National Institutes of Health (NIH) consensus definition of mild BPD); (3) "modern": need for additional oxygen at 36 weeks postmenstrual age (i.e., the NIH consensus definition of moderate or severe BPD). The evaluated studies included randomised trials, prospective cohort, retrospective cohort, and case control studies. The meta-analysis of unadjusted (OR 1.89) and adjusted (OR 1.58) showed a significant association between chorioamnionitis and BPD. The limitations of these analyses were that (1) the comparison groups within the studies were other preterm infants likely to be affected by vascular and other placental pathologies, also associated with perinatal inflammation and neonatal morbidity such as BPD [56, 57]; (2) gestational age and birthweight were confounding factors; (3) there was substantial heterogeneity across studies in the magnitude of the association between chorioamnionitis and BPD, and whether or not the association was statistically significant; (4) the heterogeneity remained after grouping studies by...
type of chorioamnionitis, definition of BPD, and whether the study included only very low birth weight infants or all preterm infants; (5) events such as exposure to antenatal steroids, postnatal sepsis, administration of surfactant, mode of ventilation, and patent ductus arteriosus were not known to be potential confounding factors at the time many of the studies were undertaken and therefore were not recorded; (6) the definition of chorioamnionitis was not consistent across the studies, and for instance, recent studies suggest that markers of fetal inflammatory response (leukocytosis or funisitis) are associated with the development of BPD, whereas chorioamnionitis alone is not [58, 59]; (7) the impact of ethnicity and the genetic background on the risk of BPD cannot be underestimated [36]; (8) the authors also found significant publication bias, and after controlling for publication bias for the adjusted data, the result was no longer significant; (9) also, the studies where the primary objective was not about the association between chorioamnionitis versus BPD showed no significant association, whereas studies reporting chorioamnionitis versus BPD as the primary objective were more likely to report a significant association; (10) the authors were restricted to data presented in the published reports and did not always have detailed information to control for important confounders, for instance, the gestational age; (11) the authors had to rely on the adjusted analyses as presented in the published reports and the variables which they included, which were not consistent across studies.

A study performed at our unit in order to assess the association between histological chorioamnionitis and BPD revealed a significant unadjusted association (OR 2.45 (95% CI: 1.16–5.18)), but when adjusted for gestational age and birthweight the association was no longer significant (OR 1.2 (95% CI: 0.51–2.95)) [60].

Been and Zimmermann [11] also reviewed the evidence of the association between intratructerine inflammation and pulmonary outcome. The authors also found numerous factors implicated in the interpretation of the results and that may explain, at least, part of the paradoxical findings among different studies. Inclusion criteria differ greatly among studies. Gestational age and birthweight differences were likely to affect results in some studies. Some studies selected their cohort by including only ventilated infants, or patients with premature prolonged rupture of membranes (PPROM), preterm labour, and suspected clinical chorioamnionitis. In contrast, cases of clinical chorioamnionitis or suspected maternal infection were excluded by others. Histopathological criteria and grading systems for diagnosing chorioamnionitis or fetal inflammation differ importantly between studies. The different definition of BPD complicates comparison of outcomes. Only a limited number of studies have adjusted the association for gestational age and birth weight. Some studies have performed multivariate models for other confounding factors without mentioning them, a fact that further complicates comparison of data.

Small for gestational age and intrauterine growth restriction are fetal conditions that increase the risk of BPD and prolong the duration of mechanical ventilation in preterm infants younger than 32 weeks of gestation [61–63]. The main mechanisms to explain how intrauterine growth restriction modulates the risk of a BPD have been described in animals. In experimentally growth restricted preterm lambs, impaired growth of terminal airways, gas exchange units, and blood vessels have been shown [64, 65]. Furthermore, growth restriction leads to reduced expression of surfactant protein mRNA and could induce increase inflammatory activation [64]. In a study performed at our center, we found a different profile of cytokines in venous cord blood of small for gestational age preterm newborns and the association of low levels of venous cord blood IL-6 and IL-10 and moderate/severe BPD in small for gestational age preterm newborns [66].

Racial differences in chorioamnionitis prevalence and the pulmonary response to intratructerine inflammation may account for additional inconsistencies between studies, as chorioamnionitis and vaginal bacterial colonisation are more prevalent in non-White [46, 67, 68], while White race has a higher prevalence of BPD [46, 69]. Another factor is that over the time period the cohort study data have been collected, important changes in general practice in neonatal intensive care have taken place. The widespread implementation of antenatal steroids is the most obvious and probably the most influential example [70]. Other practice changes include the increased use of exogenous surfactant [71] and noninvasive modes of ventilatory support such as continuous positive airway pressure (CPAP) [72]. These may reduce secondary lung injury in chorioamnionitis-exposed infants and partly account for the apparently diminishing association between chorioamnionitis and BPD over time [73].

Probably the most informative study concerning indirect evidence of a link between chorioamnionitis and BPD is that reported by Van Marter and colleagues [73]. In a case-control design, very low birth weight infants with BPD were matched with infants without BPD on gestational age, birth weight, and hospital specific treatment strategies. In these infants chorioamnionitis was associated with a decreased risk for BPD if infants were ventilated for less than seven days. However, when infants were exposed to mechanical ventilation for more than seven days or had sepsis, chorioamnionitis significantly increased BPD risk, the effect being the most prominent with all three risk factors present. This suggests that while antenatal exposure to inflammation in itself may reduce BPD risk, it increases the susceptibility of the lung to postnatal injurious events.

6. Chorioamnionitis and Long-Term Respiratory Outcome

The association between chorioamnionitis and pulmonary outcome beyond the neonatal period has not been extensively studied. No significant differences in the use of supplemental oxygen, bronchodilators, and systemic or inhaled steroids were reported between patients with and without chorioamnionitis at 18–22 months’ corrected age in the hydrocortisone trial, irrespective of neonatal hydrocortisone treatment [74]. In the study of Kumar and colleagues [75], chorioamnionitis and prematurity were shown to have a joint predisposing effect on recurrent wheezing and physician-diagnosed asthma at a mean age of 2.2 years, mainly in
African-American children. Further investigation of the long-term effect of chorioamnionitis on respiratory outcome is warranted.

7. Conclusions

There is a strong evidence that histologic chorioamnionitis is associated with a reduction of incidence and severity of RDS. Short-term maturational effects on the lungs of extremely premature infants seem to be, however, accompanied by a greater susceptibility of the lung, eventually contributing to an increased risk of BPD. Genetic susceptibility to BPD is an evolving area of research and several studies have directly related the risk of BPD to genomic variants. There is a substantial heterogeneity across the studies in the magnitude of the association between chorioamnionitis and BPD, and whether or not the association is statistically significant. Considerable variation is largely depending on differences in inclusion and exclusion criteria, as well as on clinical and histopathological definitions. The presence of significant publication bias may exaggerate the magnitude of the association. Controlling for publication bias may conduct to adjusted results that are no longer significant. Recent studies generally seem to confirm the effect of chorioamnionitis on RDS incidence, while no effect on BPD is seen.

Additional research is needed to explore the effect of antenatal inflammation on the early and late pulmonary outcome of the extreme premature newborn.

References

[1] K. L. Watterberg, L. M. Demers, S. M. Scott, and S. Murphy, “Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops,” *Pediatrics*, vol. 97, no. 2, pp. 210–215, 1996.

[2] R. L. Goldenberg, J. C. Hauth, and W. W. Andrews, “Intrauterine infection and preterm delivery,” *The New England Journal of Medicine*, vol. 342, no. 20, pp. 1500–1507, 2000.

[3] M. M. Lahra and H. E. Jeffery, “A fetal response to chorioamnionitis is associated with early survival after preterm birth,” *The American Journal of Obstetrics and Gynecology*, vol. 190, no. 1, pp. 147–151, 2004.

[4] M. M. Lahra, P. J. Beeby, and H. E. Jeffery, “Maternal versus fetal inflammation and respiratory distress syndrome: a 10-year hospital cohort study,” *Archives of Disease in Childhood*, vol. 94, no. 1, pp. F13–F16, 2009.

[5] E. Dempsey, M. F. Chen, T. Kokottis, D. Vallerand, and R. Usher, “Outcome of neonates less than 30 weeks gestation with histologic chorioamnionitis,” *The American Journal of Perinatology*, vol. 22, no. 3, pp. 155–159, 2005.

[6] A. H. Jobe and E. Bancalari, “Bronchopulmonary dysplasia,” *The American Journal of Respiratory and Critical Care Medicine*, vol. 163, no. 7, pp. 1723–1729, 2001.

[7] I. R. S. Sosenko and E. Bancalari, “New developments in the presentation, pathogenesis, epidemiology, and prevention of bronchopulmonary dysplasia,” in *The Newborn Lung*. E. Bancalari, Ed., pp. 187–207, Saunders Elsevier, Philadelphia, Pa, USA, 2008.

[8] R. D. Bland, “Neonatal chronic lung disease in the post-surfactant era,” *Biology of the Neonate*, vol. 88, no. 3, pp. 181–191, 2005.

[9] B. W. Kramer, S. Kallapur, J. Newnham, and A. H. Jobe, “Prenatal inflammation and lung development,” *Seminars in Fetal and Neonatal Medicine*, vol. 14, no. 1, pp. 2–7, 2009.

[10] A. H. Jobe and S. G. Kallapur, “Chorioamnionitis, surfactant, and lung disease in very low birth weight infants,” *Journal of Pediatrics*, vol. 156, no. 1, pp. 3–4, 2010.

[11] J. V. Been and L. J. I. Zimmermann, “Histological chorioamnionitis and respiratory outcome in preterm infants,” *Archives of Disease in Childhood*, vol. 94, no. 3, pp. F218–F225, 2009.

[12] L. Hartling, Y. Liang, and T. Lacaze-Masmonteil, “Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis,” *Archives of Disease in Childhood*, vol. 97, no. 1, pp. F8–F17, 2012.

[13] B. W. Kramer, “Chorioamnionitis: new ideas from experimental models,” *Neonatology*, vol. 99, no. 4, pp. 320–325, 2011.

[14] L. S. Prince, H. I. Dieperink, V. O. Okoh, G. A. Fierro-Perez, and R. L. Lallone, “Toll-like receptor signaling inhibits structural development of the distal fetal mouse lung,” *Developmental Dynamics*, vol. 233, no. 2, pp. 553–561, 2005.

[15] K. Bry, J. A. Whitsett, and U. Lappalainen, “IL-1β disrupts postnatal lung morphogenesis in the mouse,” *The American Journal of Respiratory Cell and Molecular Biology*, vol. 36, no. 1, pp. 32–42, 2007.

[16] E. Bäckström, A. Hogmalm, U. Lappalainen, and K. Bry, “Developmental stage is a major determinant of lung injury in a murine model of bronchopulmonary dysplasia,” *Pediatric Research*, vol. 69, no. 4, pp. 312–318, 2011.

[17] C. Romero and T. J. Garite, “Twenty percent of very preterm neonates (23–32 weeks of gestation) are born with bacteremia caused by genital Mycoplasmas,” *The American Journal of Obstetrics and Gynecology*, vol. 198, no. 1, pp. 1–3, 2008.

[18] F. Grattard, B. Soleihac, B. De Barbeyrac, C. Bebear, P. Sheffert, and B. Pozzetto, “Epidemiologic and molecular investigations of genital Mycoplasmas from women and neonates at delivery,” *The Pediatric Infectious Disease Journal*, vol. 14, pp. 853–858, 1995.

[19] R. L. Goldenberg, W. W. Andrews, A. R. Goepfert et al., “The Alabama Preterm Birth Study: umbilical cord blood Ureaplasma urealyticum and Mycoplasmas hominis cultures in very preterm newborn infants,” *The American Journal of Obstetrics and Gynecology*, vol. 198, no. 1, pp. 43.e1–45.e1, 2008.

[20] R. M. Viscardi, N. Hashmi, G. W. Gross, C. C. J. Sun, A. Rodriguez, and K. D. Fairchild, “Incidence of invasive Ureaplasma in VLBW infants: relationship to severe intraventricular hemorrhage,” *Journal of Perinatology*, vol. 28, no. 11, pp. 759–765, 2008.

[21] R. M. Viscardi and J. D. Hasday, “Role of Ureaplasma species in neonatal chronic lung disease: epidemiologic and experimental evidence,” *Pediatric Research*, vol. 65, no. 5, pp. 84R–90R, 2009.

[22] M. J. Novy, L. Duffy, M. K. Axthelletal., “Ureaplasma parvum or Mycoplasma hominis as sole pathogens cause chorioamnionitis, preterm delivery, and fetal pneumonia in rhesus macaques,” *Reproductive Sciences*, vol. 16, no. 1, pp. 56–70, 2009.

[23] L. Hee, “Likelihood ratios for the prediction of preterm delivery with biomarkers,” *Acta Obstetricia et Gynecologica Scandinavica*, vol. 90, no. 11, pp. 1189–1199, 2011.

[24] G. Estrada-Gutierrez, N. Gomez-Lopez, E. Zaga-Clavellina et al., “Interaction between pathogenic bacteria and intrauterine leukocytes triggers alternative molecular signaling cascades
leading to labor in women," *Infection and Immunity*, vol. 78, no. 11, pp. 4792–4799, 2010.

[25] R. L. Schelonka, B. Katz, K. B. Waites, and D. K. Benjamin Jr., "Critical appraisal of the role of *Ureaplasma* in the development of bronchopulmonary dysplasia with metaanalytic techniques," *Pediatric Infectious Disease Journal*, vol. 24, no. 12, pp. 1033–1039, 2005.

[26] B. A. Yoder, J. J. Coalson, V. T. Winter, T. Siler-Khodr, L. B. Duffy, and G. H. Cassell, "Effects of antenatal colonization with *Ureaplasma urealyticum* on pulmonary disease in the immature baboon," *Pediatric Research*, vol. 54, no. 6, pp. 797–807, 2003.

[27] D. C. Kasper, T. P. Mechtler, J. Böhm et al., "In utero exposure to *Ureaplasma* spp. is associated with increased rate of bronchopulmonary dysplasia and intraventricular hemorrhage in preterm infants," *Journal of Perinatal Medicine*, vol. 39, no. 3, pp. 331–336, 2011.

[28] A. C. Okogbule-Wonodi, G. W. Gross, C. C. J. Sun et al., "Necrotizing enterocolitis is associated with *Ureaplasma* colonization in preterm infants," *Pediatric Research*, vol. 69, no. 5, pp. 442–447, 2011.

[29] R. M. Viscardi, W. M. Manimtim, C. C. J. Sun, L. Duffy, and G. H. Cassell, "Lung pathology in premature infants with *Ureaplasma urealyticum* infection," *Pediatric and Developmental Pathology*, vol. 5, no. 2, pp. 141–150, 2002.

[30] R. M. Viscardi, W. M. Manimtim, J. R. He et al., "Disordered pulmonary myofibroblast distribution and elastin expression in preterm infants with *Ureaplasma urealyticum* pneumonitis," *Pediatric and Developmental Pathology*, vol. 9, no. 2, pp. 143–151, 2006.

[31] R. M. Viscardi, S. P. Atamas, I. G. Luzina et al., "Antenatal *Ureaplasma urealyticum* respiratory tract infection stimulates proinflammatory, profibrotic responses in the preterm baboon lung," *Pediatric Research*, vol. 60, no. 2, pp. 141–146, 2006.

[32] E. Normann, T. Lacaze-Masmonteil, F. Eaton, L. Schwendimann, P. Gressens, and B. Thébaut, "A novel mouse model of *Ureaplasma*-induced perinatal inflammation: effects on lung and brain injury," *Pediatric Research*, vol. 65, no. 4, pp. 430–436, 2009.

[33] G. Bokodi, A. Treszl, L. Kovács, T. Tulassay, and B. Vásárhelyi, "Dysplasia: a review," *Pediatric Pulmonology*, vol. 42, no. 10, pp. 952–961, 2007.

[34] G. Rocha, E. Proença, A. Areias et al., "HLA and bronchopulmonary dysplasia susceptibility: a pilot study," *Disease Markers*, vol. 31, no. 4, pp. 199–203, 2011.

[35] M. Hallman, R. Marttila, R. Pertile, M. Ojaniemi, and R. Haataja, "Genes and environment in common neonatal lung disease," *Neonatology*, vol. 91, no. 4, pp. 298–302, 2007.

[36] P. M. Lavoie and M. P. Dubé, "Genetics of bronchopulmonary dysplasia in the age of genomics," *Current Opinion in Pediatrics*, vol. 22, no. 2, pp. 134–138, 2010.

[37] R. W. Redline, "Inflammatory responses in the placenta and umbilical cord," *Seminars in Fetal and Neonatal Medicine*, vol. 11, no. 5, pp. 296–301, 2006.

[38] L. J. Muglia and M. Katz, "The enigma of spontaneous preterm birth," *The New England Journal of Medicine*, vol. 362, no. 6, pp. 529–535, 2010.

[39] L. Cao, J. Wang, I. Tseu, D. Luo, and M. Post, "Maternal exposure to endotoxin delays alveolarization during postnatal rat lung development," *The American Journal of Physiology*, vol. 296, no. 5, pp. L726–L737, 2009.

[40] S. G. Kallapur and A. H. Jobe, "Contribution of inflammation to lung injury and development," *Archives of Disease in Childhood*, vol. 91, no. 2, pp. F132–F135, 2006.

[41] R. Mehta, S. Nanjundaswamy, S. Shen-Schwarz, and A. Petrova, "Neonatal morbidity and placental pathology," *Indian Journal of Pediatrics*, vol. 73, no. 1, pp. 25–28, 2006.

[42] A. Kent and J. E. Dahlstrom, "Chorioamnionitis/ funisitis and the development of bronchopulmonary dysplasia," *Journal of Paediatrics and Child Health*, vol. 40, no. 7, pp. 356–359, 2004.

[43] C. J. Holcroft, F. B. Askin, A. Patra, M. C. Allen, K. J. Blakemore, and E. M. Graham, "Are histopathologic chorioamnionitis and funisitis associated with metabolic acidosis in the preterm fetus?" *The American Journal of Obstetrics and Gynecology*, vol. 191, no. 6, pp. 2010–2015, 2004.

[44] R. Mittendorf, R. Covert, A. G. Montag et al., "Special relationships between fetal inflammatory response syndrome and bronchopulmonary dysplasia in neonates," *Journal of Perinatal Medicine*, vol. 33, no. 5, pp. 428–434, 2005.

[45] B. S. Richardson, E. Wäkim, O. da Silva, and J. Walton, "Preterm histologic chorioamnionitis: impact on cord gas and pH values and neonatal outcome," *The American Journal of Obstetrics and Gynecology*, vol. 195, no. 5, pp. 1357–1365, 2006.

[46] R. W. Redline, D. Wilson-Costello, and M. Hack, "Placental and other perinatal risk factors for chronic lung disease in very low birth weight infants," *Pediatric Research*, vol. 52, no. 5, pp. 713–719, 2002.

[47] W. W. Andrews, R. L. Goldenberg, O. Faye-Petersen, S. Cliver, A. R. Goeppert, and J. C. Hauth, "The Alabama Preterm Birth study: polymorphonuclear and mononuclear cell placental infiltrations, other markers of inflammation, and outcomes in 23- to 32-week preterm newborn infants," *The American Journal of Obstetrics and Gynecology*, vol. 195, no. 3, pp. 803–808, 2006.

[48] S. C. Dexte, H. Pinar, M. P. Malee, J. Hogan, M. W. Carpenter, and B. R. Vohr, "Outcome of very low birth weight infants with histopathologic chorioamnionitis," *Obstetrics and Gynecology*, vol. 96, no. 2, pp. 172–177, 2000.

[49] A. Elimian, U. Verma, D. Beneck, R. Cipriano, P. Visintainer, and N. Tejani, "Histologic chorioamnionitis, antenatal steroids, and perinatal outcomes," *Obstetrics and Gynecology*, vol. 96, no. 2, pp. 333–336, 2000.

[50] D. Ogusyemi, M. Murillo, U. Jackson, N. Hunter, and B. Alpers, "The relationship between placental histopathology findings and perinatal outcome in preterm infants," *Journal of Maternal-Fetal and Neonatal Medicine*, vol. 13, no. 2, pp. 102–109, 2003.

[51] C. De Felice, P. Toti, S. Parrini et al., "Histologic chorioamnionitis and severity of illness in very low birth weight newborns," *Pediatric Critical Care Medicine*, vol. 6, no. 3, pp. 298–302, 2005.

[52] S. C. Mu, C. H. Lin, Y. L. Chen et al., "Impact on neonatal outcome and anthropometric growth in very low birth weight infants with histological chorioamnionitis," *Journal of the Foman Medical Association*, vol. 107, no. 4, pp. 304–310, 2008.

[53] S. Kosuge, A. Okhuchi, H. Minakami et al., "Influence of chorioamnionitis on survival and morbidity in singletons live-born at < 32 weeks of gestation," *Acta Obstetrica et Gynecologica Scandinavica*, vol. 79, no. 10, pp. 861–865, 2000.

[54] T. Kaukola, J. Tuimala, R. Herva, S. Kingsmore, and M. Hallman, "Cord immunoproteins as predictors of respiratory outcome in preterm infants," *The American Journal of Obstetrics and Gynecology*, vol. 200, no. 1, pp. 100.e1–100.e1, 2009.
[55] I. Bersani, W. Thomas, and C. P. Speer, “Chorioamnionitis: the good or the evil for neonatal outcome?” *Journal of Maternal-Fetal and Neonatal Medicine*, vol. 25, supplement 1, pp. 12–16, 2012.

[56] T. F. McElrath, J. L. Hecht, O. Dammann et al., “Pregnancy disorders that lead to delivery before the 28th week of gestation: an epidemiologic approach to classification,” *The American Journal of Epidemiology*, vol. 168, no. 9, pp. 980–989, 2008.

[57] C. Bose, L. J. van Marter, M. Laughon et al., “Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation,” *Pediatrics*, vol. 124, no. 3, pp. e450–e458, 2009.

[58] D. A. Paul, K. Zook, A. MacKley, and R. G. Locke, “Reduced mortality and increased BPD with histological chorioamnionitis and leukocytosis in very-low-birth-weight infants,” *Journal of Perinatology*, vol. 30, no. 1, pp. 58–62, 2010.

[59] J. V. Been, I. G. Rours, R. F. Kornelisse, F. Jonkers, R. R. de Krijger, and L. J. Zimmermann, “Chorioamnionitis Alters the response to surfactant in preterm infants,” *Journal of Pediatrics*, vol. 156, no. 1, pp. 10.e1–15.e1, 2010.

[60] G. Rocha, E. Proença, C. Quintas, T. Rodrigues, and H. Guimarães, “Chorioamnionitis and neonatal morbidity,” *Acta Medica Portuguesa*, vol. 19, no. 3, pp. 207–212, 2006.

[61] G. Kewitz, S. Wudel, H. Hopp, W. Hopfenmüller, M. Vogel, and I. Roots, “Below median birth weight in appropriate-for-gestational-age preterm infants as a risk factor for bronchopulmonary dysplasia,” *Journal of Perinatal Medicine*, vol. 36, no. 4, pp. 359–364, 2008.

[62] J. Zeitlin, M. El Ayoubi, P. H. Jarreau et al., “Impact of fetal growth restriction on mortality and morbidity in a very preterm birth cohort,” *Journal of Pediatrics*, vol. 157, no. 5, pp. 733.e1–739.e1, 2010.

[63] L. J. Van Marter, O. Dammann, E. N. Allred et al., “Chorioamnionitis, mechanical ventilation, and postnatal sepsis as modulators of chronic lung disease in preterm infants,” *Journal of Pediatrics*, vol. 140, no. 2, pp. 171–176, 2002.

[64] K. L. Watterberg, M. L. Shaffer, M. J. Mishefske et al., “Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants,” *Pediatrics*, vol. 120, no. 1, pp. 40–48, 2007.

[65] R. Kumar, Y. Yu, R. E. Story et al., “Prematurity, chorioamnionitis, and the development of recurrent wheezing: a prospective birth cohort study,” *Journal of Allergy and Clinical Immunology*, vol. 121, no. 4, pp. 878.e6–884.e6, 2008.